Monograph

J05AH01 - Zanamivir

Not porphyrinogenic

Rationale

Insignificant systemic exposure. The substance is not metabolised and does not interact with CYPs.

Chemical description

Antiviral neuramidase inhibitor used (inhalation 2x5 mg twice daily for 5 days) in symptomatic influenza A and B in adults and children > 12 years. The dose is deposited (about 80%) in oropharynx. Eliminated from there to the gastrointestinal tract with bioavailability of only 2 %. No metabolism takes place. No interaction with the metabolism of other drugs is observed.

Similar drugs

Explore alternative drugs in similar therapeutic classes J05A / J05AH or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

Dectova · Dectova 10 mg/ml, oplossing voor infusie · Relenza · Relenza 5 mg/dosis inhalatiepoeder, voorverdeeld

Belgium

Dectova · Dectova 10 mg/ml sol. perf. i.v. flac. · Relenza · Relenza 5 mg/dose pdr. inhal. (récip. unidose)

United Kingdom

Dectova · Dectova 200mg/20ml solution for infusion vials · Relenza · Relenza 5mg inhalation powder blisters with Diskhaler · Zanamivir · Zanamivir 200mg/20ml solution for infusion vials

Denmark